CytomX Therapeutics, Inc. (CTMX) vs Phathom Pharmaceuticals, Inc. (PHAT)
CytomX Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. CytomX Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are of similar size ($599.2M and $572.8M). Phathom Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 110.2% against −87.0%. Phathom Pharmaceuticals, Inc. has the higher net margin (−41.3% vs −451.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Phathom Pharmaceuticals, Inc. leads on 12 and CytomX Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | CTMX | PHAT | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 82.92% | 65.16% |
| Operating margin | (476.19%) | (16.96%) | 0.00% |
| Net margin | (451.62%) | (41.34%) | 0.00% |
| Free cash flow margin | (450.27%) | (15.40%) | 0.00% |
| Return on equity | (39.18%) | 26.42% | (57.72%) |
| Return on assets | (29.72%) | (34.32%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack